IXICO’s Post

We’ll be at AAIC hosted by Alzheimer's Association® on July 28th – August 1st in Philadelphia, USA! Robin Wolz will be presenting posters on our latest work in understanding Alzheimer's disease progression: 🕛 Wednesday, July 31, 2024: 7:30 AM – 4:15 PM EDT 🧠 Poster #86084  Erosion of The Supratentorial White Matter Reference for Increased Power in Longitudinal Amyloid PET 🧠 Poster #92157  Comparison of local amyloid PET uptake patterns between black and white participants in the GAP Bio-Hermes study Scott Vogel will join Robin to share imaging biomarker insights and learn from others in the Alzheimer's disease clinical research field. So whether you're an old or new friend, do stop by and say hello! Going to AAIC? Drop us a message and let us know, maybe we can schedule a time to talk! See you in Philadelphia!

Join us tomorrow for an insightful discussion on overcoming key challenges in Alzheimer's disease (AD) research, particularly the low recruitment rates of underrepresented populations. This gap limits the effectiveness of treatments across diverse demographics. Learn how improving recruitment strategies and leveraging advanced imaging biomarkers like amyloid PET can enhance AD clinical trial design. What You’ll Learn: 🔹 Inclusive Research: The importance of diversity in clinical trials, with insights from the Bio-Hermes study. 🔹Equity in Healthcare: How diverse participation leads to more equitable healthcare solutions. 🔹Neuroimaging: Interpretation of PET imaging biomarkers in multi-center clinical trials. Webinar Details: 📅 Date: Tuesday, June 25th, 2024 🕓 Time: 3pm BST / 4pm CET / 10am EDT 🎙️ Speakers: ➡ Richard Mohs, Chief Science Officer – Global Alzheimer's Platform Foundation ➡ Robin Wolz, Chief Scientific Officer – IXICO Register here:https://lnkd.in/gfgz68St

Next week, join us as we tackle the critical challenges in Alzheimer's disease (AD) research, including the low recruitment rates of underrepresented populations. This issue hinders the development of effective treatments for all demographics. However, we can significantly enhance AD clinical trial design by improving recruitment strategies and utilizing advanced imaging biomarkers like amyloid PET. Don't miss our upcoming webinar with experts Richard Mohs and Robin Wolz, who will explore these vital topics and share recent advances in recruitment and imaging biomarkers. What You’ll Learn: 🔹 Inclusive Research: The importance of diversity in clinical trials, with insights from the Bio-Hermes study. 🔹Equity in Healthcare: How diverse participation leads to more equitable healthcare solutions. 🔹Neuroimaging: Interpretation of PET imaging biomarkers in multi-center clinical trials. Webinar Details: 📅 Date: Tuesday, June 25th, 2024 🕓 Time: 3pm BST / 4pm CET / 10am EDT 🎙️ Speakers: ➡ Richard Mohs, Chief Science Officer – Global Alzheimer's Platform Foundation’s ➡ Robin Wolz, Chief Scientific Officer – IXICO Register here: https://lnkd.in/gfgz68St

Join us at the 9th annual Future of Healthcare Investment Forum 2024 hosted by the LSEG (London Stock Exchange Group) this Wednesday, 19 June 2024, where our CEO, Giulio Cerroni, and CSO, Robin Wolz, will be joining the many healthcare leaders to discuss the current and future state of neurodegenerative clinical research. Robin will be discussing our work in using AI-driven neuroimaging analysis to advance and revolutionize clinical research in the following panel: 🧠 Panel 2: Neurodegeneration and neuropsychology🧠 ➡Jenny Barnett, CEO, Monument Therapeutics ➡Olivia Cavlan, Chief Corporate Development and Strategy Officer, Alchemab Therapeutics Ltd ➡Lisa Deschamps, CEO, AviadoBio ➡Robin Wolz, Chief Scientific Officer, IXICO ➡Moderator: Kevin Grogan, Managing Editor Europe, Scrip Robin and Giulio look forward to discussing the future of AI-driven imaging and neurodegenerative research with the community at the forum. ➡ For more details on the forum and the panel, visit: https://lnkd.in/giaWVhEn

Navigating the challenges in Alzheimer's disease (AD) research requires innovative solutions. One major hurdle is the low recruitment rates of traditionally underrepresented populations in clinical trials. This gap hinders the development of treatments that are effective for all demographics. However, we can change AD clinical trial design by improving recruitment rates and utilizing advanced imaging biomarkers like amyloid PET. Join our upcoming webinar with industry experts Richard Mohs and Robin Wolz to explore these key topics.   What You’ll Learn: ➡ Inclusive Research: The importance of diversity in clinical trials, with insights from the Bio-Hermes-001 study. ➡Equity in Healthcare: How diverse participation leads to more equitable healthcare solutions. ➡Neuroimaging: Interpretation of PET imaging biomarkers in multi-center clinical trials. Webinar Details: 📅 Date: Tuesday, June 25th, 2024  🕓 Time: 3pm BST / 4pm CET / 10am EDT ➡ Registration: https://lnkd.in/gfgz68St 🎙️ Speakers: Richard Mohs, Chief Science Officer – Global Alzheimer's Platform Foundation Robin Wolz, Chief Scientific Officer – IXICO

Unlock the future of Alzheimer's research with inclusive clinical trials, recruitment strategies, and cutting-edge imaging biomarkers. Join our upcoming webinar on enhancing the recruitment of underrepresented populations in Alzheimer's disease (AD) research. Discover the challenges in AD trial design and the use of amyloid and tau PET imaging biomarkers. What You’ll Learn: Inclusive Research: The importance of diversity in clinical trials, with insights from the Bio-Hermes study. Equity in Healthcare: How diverse participation leads to more equitable healthcare solutions. Neuroimaging: Interpretation of PET imaging biomarkers in multi-center clinical trials.   Webinar Details: 📅 Date: Tuesday, June 25th, 2024  🕓 Time: 3pm BST / 4pm CET / 10am EDT 🎙️ Speakers: ➡ Richard Mohs, Chief Science Officer – Global Alzheimer's Platform Foundation’s Platform Foundation ➡ Robin Wolz, Chief Scientific Officer – IXICO Register here: https://lnkd.in/gfgz68St

On Wednesday, 19 June 2024, our CEO, Giulio Cerroni, and CSO, Robin Wolz, will attend the 9th annual Future of Healthcare Investment Forum 2024 hosted by the LSEG (London Stock Exchange Group). Robin will be discussing our work in using AI-driven neuroimaging analysis to advance and revolutionize clinical research in the following panel: 🧠 Panel 2: Neurodegeneration and neuropsychology🧠 ➡ Jenny Barnett, CEO, Monument Therapeutics ➡Olivia Cavlan, Chief Corporate Development and Strategy Officer, Alchemab Therapeutics Ltd ➡Lisa Deschamps, CEO, AviadoBio ➡Robin Wolz, Chief Scientific Officer, IXICO ➡Moderator: Kevin Grogan, Managing Editor Europe, Scrip Robin and Giulio are eager to discuss the future of AI-driven imaging and neurodegenerative research with the community at the forum. ➡ For more details on the forum and the panel, visit: https://lnkd.in/giaWVhEn

Improving the recruitment rate of traditionally underrepresented populations in AD research is a key consideration for sponsors designing AD clinical trials. This webinar provides an overview on associated challenges for AD trial design and looks at some of the approaches that can be implemented to increase recruitment rates. The webinar furthermore looks at implications and open questions on various biomarkers, in particular amyloid PET imaging. 📅 Date: Tuesday, June 25th, 2024  🕓 Time: 3pm BST / 4pm CET / 10am EDT  🎙️ Speakers:  • Richard Mohs, Chief Science Officer – Global Alzheimer's Platform Foundation’s • Robin Wolz, Chief Scientific Officer – IXICO Register here: https://lnkd.in/gfgz68St What You'll Learn: Diversity in Clinical Trials: - Inclusive Research: Understand the importance of recruiting diverse participants in clinical trials. The Bio-Hermes study emphasizes including underrepresented groups, such as Black and Non-white Hispanic populations, who are disproportionately affected by AD. - Equity in Healthcare: Learn how this inclusive approach not only ensures broader applicability of research findings but also moves us closer to equitable healthcare solutions. Neuroimaging: - Biomarker interpretation: Use of PET imaging biomarkers for amyloid and tau has become an integral part of AD clinical trials. Learn about the interpretation of imaging biomarkers in multi-center clinical trials and how they can be used to characterize diverse subject populations. Join experts Richard Mohs and Robin Wolz as they guide us through these groundbreaking topics, offering their extensive knowledge and answering your questions. This webinar is a unique opportunity to understand how the latest research is paving the way for more effective and inclusive Alzheimer’s disease management. By incorporating these findings into future clinical trial designs now, we can accelerate the development of treatments that benefit everyone. Don’t miss this chance to be part of a pivotal discussion. Register now to join us on this journey towards a brighter future for Alzheimer’s disease management.

We're proud to announce that we have signed a contract with the Global Alzheimer's Platform Foundation® ("GAP") to support GAP's planned Bio-Hermes 2 trial which will last 48 months. In the Bio-Hermes 2 trial, IXICO will apply its expertise to qualify approximately 30 participating imaging centres for the collection of amyloid PET and tau PET molecular imaging and MR Imaging scans from approximately 1,200 volunteers over the age of 60. The volunteers will be screened for Preclinical Alzheimer's Disease, Prodromal AD, or Mild Dementia AD, with IXICO providing both visual read and AI driven quantitative analysis across all three imaging modalities used in the Bio-Hermes 2 trial. Giulio Cerroni, Chief Executive Officer of IXICO, commented: "We are delighted to deepen our long-term strategic partnership with GAP by building on the success of the initial Bio-Hermes trial to now also be selected to deliver all of the imaging analysis requirements of the Bio-Hermes 2 trial across both MRI and PET. With the significant unmet medical need for new therapies in Alzheimer's Disease, we are excited about the prospects of deepening our collaboration with GAP in support of the success of the Bio-Hermes 2 trial." John Dwyer, President of the Global Alzheimer's Platform Foundation (GAP), commented: "Our collaboration with IXICO for neuroimaging and AI-driven quantitative analysis is a fundamental element of GAP's innovative Bio-Hermes 2 trial, which is taking a novel approach to incorporate a broad set of digital and blood biomarker results for comparison across cognitively normal and impaired individuals. We've also committed to an unprecedented level of participation by traditionally underrepresented populations in AD studies so that the insights generated by BH2 will benefit everyone impacted by Alzheimer's and related dementias." Read more here: https://lnkd.in/gMTJip74